Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Tyrosine Protein Kinase Lyn, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tyrosine Protein Kinase Lyn and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Tyrosine Protein Kinase Lyn Overview
3. Therapeutics Development
4. Pipeline Products for Tyrosine Protein Kinase Lyn - Overview
5. Pipeline Products for Tyrosine Protein Kinase Lyn - Comparative Analysis
6. Tyrosine Protein Kinase Lyn - Therapeutics under Development by Companies
7. Tyrosine Protein Kinase Lyn - Therapeutics under Investigation by Universities/Institutes
8. Tyrosine Protein Kinase Lyn Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Tyrosine Protein Kinase Lyn - Products under Development by Companies
13. Tyrosine Protein Kinase Lyn - Products under Investigation by Universities/Institutes
14. Tyrosine Protein Kinase Lyn - Companies Involved in Therapeutics Development

• AB Science SA
• Boehringer Ingelheim GmbH
• Deciphera Pharmaceuticals, LLC
• Pfizer Inc.

For more information about this report visit http://www.researchandmarkets.com/research/rfl66d/tyrosine_protein

Related Topics: Oncology Drugs , Enzymes